Mario Rovirosa – CEO, Ferrer
Ferrer’s CEO, Mario Rovirosa, outlines how he and a new management team have been building the foundation of the Spanish mid-cap’s transformation to become a specialty pharma company, a 180-degree…
Founded in 1959, Ferrer is a Spanish multinational privately-held pharmaceutical company headquartered in Barcelona with a presence in over 90 countries. They operate in the pharmaceutical, health, fine chemicals (API), and food sectors. The company has expertise in the fields of cardiology, central nervous system, dermatology, gastroenterology, metabolism, oncology, musculoskeletal system, paediatrics, pain management, and respiratory.
Ferrer’s CEO, Mario Rovirosa, outlines how he and a new management team have been building the foundation of the Spanish mid-cap’s transformation to become a specialty pharma company, a 180-degree…
Alejandro Mora, Ferrer’s country manager for Central America & Caribbean, discusses the complexity of the region’s healthcare systems, the company’s strategy to compete against local players, and the importance for…
Xavier Rams, General Director at Ferrer Mexico, explains the importance of aligning corporate strategy to public healthcare goals in order to succeed in the dynamic Mexican environment and showcases the…
CPH Pharma was the oldest running pharmaceutical company in Portugal until its acquisition by Grupo Ferrer in 2008. Since then, the company has continued to thrive in the marketplace despite…
Our business model is new in the Chilean market and enables us with great flexibility and allows us to focus on demand generation. For Ferrer this is a great window…
In the second part of a two-part interview, Generika Philippines co-founders, Teodoro Ferrer and Julien Bello, go on to discuss the future of generic medicines in the Philippines, the compnay’s…
In part one of a two-part interview, Generika Philippines co-founders Teodoro Ferrer and Julien Bello discuss what led them to start the company, the changing mentality among the Filipino population…
Having moved early on a promising phase II monoclonal antibody, Almirall is inching closer to entering the Sanofi-dominated European market for eczema after posting, along with Eli Lilly, positive phase…
Almirall CEO Gianfranco Nazzi dives into the new strategic focus of the global biopharmaceutical company with HQ in Barcelona as it seeks to serve the European medical dermatology market. The…
ADL Biopharma is a Spanish CDMO and, according to its CEO, owner of Europe’s largest fermenter. Ignacio Urbelz, CEO, reveals how, after a tumultuous time that saw the company go…
Way before securing the CEO role at Esteve in 2018, Staffan Schüberg built a career that saw him rise through the ranks of Lundbeck, from commercial activities in Sweden to…
Ignacio Vega, CEO of Cardiva and Cardivais, a Spanish medtech producer and distributor, explains how, as a manufacturer of PPE, the company had to reconfigure its production operations to supply…
Esteve’s CEO outlines the transformation journey of the Spanish company after taking over in 2018, commenting on how the divestment of its generics business has helped the company lay the…
Teva’s general manager for Spain and Portugal, Juan Carlos Conde Ibarra, dives into the recently announced strategy for the affiliate, including the move to a single brand in generics, and…
Margarita Alfonsel, general secretary of Fenin, the Spanish Federation of Healthcare Technology Companies, reflects on the COVID-19 pandemic, the changing dynamics of the medical technology industry in Spain, and comments…
AseBio is the association promoting the development of the Spanish biotechnology industry. Its general manager, Ion Arocena, lays out the main priorities for the country’s sector, including the need to…
Kern Pharma’s chairman and Grupo Indukern CEO, Raúl Díaz-Varela, explains the new strategic direction of the Spanish generics player, how their partnership with Celltrion to commercialise biosimilars has evolved, and…
HIPRA is a world-leading animal health company that has launched a record 22 animal vaccines in the last 10 years. During the COVID-19 pandemic, the European company decided to jump…
The Vall d’Hebron Institute of Oncology (VHIO) is a Barcelona-based institute dedicated to delivering on the promise of precision medicine in oncology – turning cancer discovery into more effective treatments…
See our Cookie Privacy Policy Here
